ReviewMolecular nutrition & food research2025
Current Advances in the Combination of Fatty Acids and Resveratrol to Fight Ocular Diseases.
Review in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Advances in the Combination of Fatty Acids and Resveratrol to Fight Ocular Diseases.Molecular nutrition & food research · 2025Review
- The controversial role of nutraceuticals vs. drugs in proliferative retinopathies.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omega-3 polyunsaturated fatty acids (PUFA) and polyphenols have attracted interest to counteract ocular diseases and more specifically age-related macular degeneration (AMD). This eye disease, which is the leading cause of irreversible blindness in industrialized countries, is characterized by damage to the central part of the retina, the macula. Despite therapeutic advances with the use of anti-vascular endothelial growth factor (VEGF) monoclonal antibodies, numerous resistance mechanisms that worsen visual impairment have been identified. In this context, we highlight the exceptional potential of polyphenols and PUFA in addressing AMD through their actions on the different molecular mechanisms involved in AMD progression. More specifically, this review focuses on the current understanding of the effects of resveratrol, as well as docosahexaenoic and eicosapentaenoic acids, two prominent omega-3 PUFA, and the combination of these compounds. We also discuss the limitations and explore future directions for the combined use of these natural products as preventive or complementary therapies to preserve vision and slow disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.